Sipilä H, Näntö V, Kangas L, Anttila M, Halme T
Farmos Group Ltd., Research Center, Turku, Finland.
Pharmacol Toxicol. 1988 Jul;63(1):62-4. doi: 10.1111/j.1600-0773.1988.tb00911.x.
The in vitro protein binding of toremifene in human serum was measured by ultracentrifugation using 3H-toremifene together with unlabeled toremifene, 50, 500, and 5000 ng/ml. Of the total radioactivity 99.7 per cent was bound to the proteins independent of the concentration of the unlabeled drug. Binding of toremifene to different protein fractions was studied by adding 3H-toremifene and 500 ng/ml of cold toremifene to normal serum. The serum samples were exposed to agarose gel electrophoresis to fractionate different proteins. The radioactivity was localized using a position-sensitive proportional counter. After that the proteins were visualized by staining. Of the total protein bound radioactivity 92 per cent was bound to albumin, about 6 per cent to beta 1 globulin fraction and about 2 per cent to a fraction between albumin and alpha 1 globulins, part of this probably to alpha 1 acid glycoprotein.
采用超速离心法,使用³H-托瑞米芬与未标记的托瑞米芬(浓度分别为50、500和5000 ng/ml),测定了托瑞米芬在人血清中的体外蛋白结合率。总放射性的99.7%与蛋白质结合,且与未标记药物的浓度无关。通过向正常血清中加入³H-托瑞米芬和500 ng/ml的冷托瑞米芬,研究了托瑞米芬与不同蛋白质组分的结合情况。血清样本经琼脂糖凝胶电泳分离不同蛋白质。使用位置敏感比例计数器定位放射性。之后通过染色使蛋白质可视化。在与蛋白质结合的总放射性中,92%与白蛋白结合,约6%与β1球蛋白组分结合,约2%与白蛋白和α1球蛋白之间的一个组分结合,其中一部分可能与α1酸性糖蛋白结合。